Clinical trial
Phase 1 Trial of Gemcitabine Combined With the Elimusertib (BAY 1895344) ATR Inhibitor With Expansion Cohorts in Advanced Pancreatic and Ovarian Cancer
NCT04616534 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase 1 Trial of Gemcitabine Combined With the Elimusertib (BAY 1895344) ATR Inhibitor With Expansion Cohorts in Advanced Pancreatic and Ovarian Cancer
- Lead sponsor
- National Cancer Institute (NCI)
- Phase
- Phase 1
- Overall status
- Active, not recruiting
- Start date
- June 1, 2021
- Completion date
- May 20, 2027
- Enrollment
- 14 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.
advanced fallopian tube carcinoma, advanced malignant solid neoplasm, advanced ovarian carcinoma, advanced pancreatic adenocarcinoma, advanced primary peritoneal carcinoma, fallopian tube high grade serous adenocarcinoma, metastatic pancreatic adenocarcinoma, ovarian high grade serous adenocarcinoma, platinum-resistant fallopian tube carcinoma, platinum-resistant ovarian carcinoma, platinum-resistant primary peritoneal carcinoma, primary peritoneal high grade serous adenocarcinoma, stage ii pancreatic cancer ajcc v8, stage iii fallopian tube cancer ajcc v8, stage iii ovarian cancer ajcc v8, stage iii pancreatic cancer ajcc v8, stage iii primary peritoneal cancer ajcc v8, stage iv fallopian tube cancer ajcc v8, stage iv ovarian cancer ajcc v8, stage iv pancreatic cancer ajcc v8, stage iv primary peritoneal cancer ajcc v8, unresectable pancreatic adenocarcinoma